Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc. (SUPN)
Filing Type: Form 8-K (Current Report)
Date: October 30, 2024
Subject: Release of new clinical data from an exploratory open-label Phase 2a study of SPN-820 for the treatment of major depressive disorder (MDD) in adults.
Key Financial Metrics
This filing is a regulatory disclosure regarding clinical trial results and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Results
The Company reported significant efficacy data for SPN-820 in the Phase 2a study:
- 4-Hour Results:
- Response rate (≥50% reduction in MADRS): 50.0%
- Remission rate (MADRS ≤10): 35.0%
- Day 10 Results:
- Response rate: 84.2%
- Remission rate: 63.2%
Guidance, Outlook, and Risks
Management Commentary: The data demonstrates a rapid response and remission profile for SPN-820 in adults with MDD.
Risks and Contingencies: The filing notes that the information is "furnished" and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, limiting liability. No specific forward-looking guidance or risk factors regarding the study were detailed in this specific text excerpt beyond the standard regulatory disclaimer.
Investor Verification Checklist
- Verify the full study design, including sample size and control group details, in the accompanying press release or clinical trial registry.
- Confirm the timeline for potential Phase 2b or Phase 3 trial initiation based on these results.
- Review the Company's most recent 10-Q or 10-K for current cash runway and liquidity status, as this 8-K does not contain financial data.
- Assess the competitive landscape for rapid-acting antidepressants to contextualize the 4-hour response rate.